We’re excited to announce that RenaissThera has been onboarded into the C-CAMP (Centre for Cellular and Molecular Platforms) incubation program — a major milestone that strengthens our commitment to advancing innovation in metabolic health and therapeutics.

As part of the C-CAMP ecosystem, RenaissThera will benefit from state-of-the-art infrastructure, expert scientific guidance, and an inspiring community of innovators working at the intersection of biotechnology and translational research. This collaboration will help us accelerate our AI-powered discovery of affordable oral small-molecule therapies targeting incretin receptors (GLP-1R and GIPR) — a promising approach to transform the treatment of obesity and diabetes.

Joining C-CAMP marks not just an opportunity for growth, but a shared vision — to bring accessible, life-changing therapies to global populations where metabolic disorders remain underserved. With C-CAMP's support, RenaissThera will focus on optimizing its lead candidates across GLPR and GIPR targets. The partnership is a powerful validation of RenaissThera portfolio and vision, positioning the company for rapid growth and market entry.

We thank the C-CAMP team for their trust and support, and we look forward to working together toward a healthier, more equitable future driven by science, technology, and collaboration.